

Marjolein J E Greuter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5339623/publications.pdf>

Version: 2024-02-01

29
papers

594
citations

687363

13
h-index

610901

24
g-index

29
all docs

29
docs citations

29
times ranked

748
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. <i>Lancet Public Health</i> , The, 2017, 2, e331-e340. | 10.0 | 114 |
| 2 | Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 304-314. | 8.1 | 99 |
| 3 | Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy. <i>Annals of Internal Medicine</i> , 2017, 167, 544. | 3.9 | 52 |
| 4 | Modeling the Adenoma and Serrated Pathway to Colorectal Cancer (ASCCA). <i>Risk Analysis</i> , 2014, 34, 889-910. | 2.7 | 35 |
| 5 | Definition of competence standards for optical diagnosis of diminutive colorectal polyps: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. <i>Endoscopy</i> , 2022, 54, 88-99. | 1.8 | 30 |
| 6 | Quality of guidelines on the management of diabetes in pregnancy: a systematic review. <i>BMC Pregnancy and Childbirth</i> , 2012, 12, 58. | 2.4 | 29 |
| 7 | Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. <i>International Journal of Cancer</i> , 2018, 143, 269-282. | 5.1 | 28 |
| 8 | Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1450-1461. | 2.5 | 26 |
| 9 | Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality—Model-Based Exploration of the Serrated Pathway. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 135-144. | 2.5 | 25 |
| 10 | Implementation of an optical diagnosis strategy saves costs and does not impair clinical outcomes of a fecal immunochemical test-based colorectal cancer screening program. <i>Endoscopy International Open</i> , 2017, 05, E1197-E1207. | 1.8 | 24 |
| 11 | The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis. <i>British Journal of Radiology</i> , 2016, 89, 20150910. | 2.2 | 21 |
| 12 | Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1430-1437. | 2.8 | 19 |
| 13 | Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening. <i>Annals of Internal Medicine</i> , 2021, 174, 1224-1231. | 3.9 | 16 |
| 14 | Validation of Microsimulation Models against Alternative Model Predictions and Long-Term Colorectal Cancer Incidence and Mortality Outcomes of Randomized Controlled Trials. <i>Medical Decision Making</i> , 2020, 40, 815-829. | 2.4 | 14 |
| 15 | Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18F-FDG-PET-CT and/or diffusion-weighted MRI. <i>BMC Cancer</i> , 2017, 17, 256. | 2.6 | 9 |
| 16 | Resilience of a FIT screening programme against screening fatigue: a modelling study. <i>BMC Public Health</i> , 2016, 16, 1009. | 2.9 | 8 |
| 17 | Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world data. <i>International Journal of Cancer</i> , 2020, 146, 2968-2978. | 5.1 | 8 |
| 18 | Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study. <i>Journal of Medical Screening</i> , 2022, 29, 72-83. | 2.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Modeling Personalized Adjuvant Treatment in Early stage colon cancer (PATTERN). European Journal of Health Economics, 2020, 21, 1059-1073. | 2.8 | 5 |
| 20 | Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening. BMC Cancer, 2018, 18, 465. | 2.6 | 4 |
| 21 | Using Metamodeling to Identify the Optimal Strategy for Colorectal Cancer Screening. Value in Health, 2021, 24, 206-215. | 0.3 | 4 |
| 22 | Guidance for setting easy-to-adopt competence criteria for optical diagnosis of diminutive colorectal polyps: a simulation approach. Gastrointestinal Endoscopy, 2021, 94, 812-822.e43. | 1.0 | 4 |
| 23 | Model-based evaluation of the cost effectiveness of 3 versus 6 months' adjuvant chemotherapy in high-risk stage II colon cancer patients. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482095411. | 3.2 | 3 |
| 24 | Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study. International Journal of Cancer, 2021, 148, 2702-2711. | 5.1 | 3 |
| 25 | Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482199571. | 3.2 | 3 |
| 26 | Methodological framework for development of competence standards for optical diagnosis in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy, 2021, 54, . | 1.8 | 2 |
| 27 | Sa1045 GUIDANCE FOR SETTING ALTERNATIVE COMPETENCE CRITERIA FOR OPTICAL DIAGNOSIS OF DIMINUTIVE COLORECTAL POLYPS, WHICH ARE EASIER TO IMPLEMENT IN DAILY PRACTICE - A SIMULATION STUDY. Gastrointestinal Endoscopy, 2019, 89, AB152-AB153. | 1.0 | 1 |
| 28 | Can a biomarker triage test reduce colonoscopy burden in fecal immunochemical test screening?. Journal of Comparative Effectiveness Research, 2020, 9, 563-571. | 1.4 | 0 |
| 29 | Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1726-1734. | 2.5 | 0 |